I-Mab CEO de­tails con­sid­er­a­tions be­hind Chi­na split, hints at po­ten­tial in-li­cens­ing

I-Mab’s CEO is hop­ing its re­cent re­or­ga­ni­za­tion — split­ting its US and Chi­na op­er­a­tions — will sim­pli­fy its in­vest­ment the­sis by shift­ing the risk pro­file and fo­cus­ing its re­sources, af­ter the biotech strug­gled to win over in­vestors.

Speak­ing at an in­vestor con­fer­ence since an­nounc­ing the Chi­na di­vesti­ture, CEO Raj Kan­nan said I-Mab was keen to re­duce its cash burn sig­nif­i­cant­ly as part of the tran­si­tion to a US-based com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER